Evidence map›Paper›PMID 42657993›Full record

SynthesisAnales del sistema sanitario de Navarra2026

Non-pharmacological interventions and quality of life in female survivors of hormone receptor-positive breast cancer receiving adjuvant endocrine therapy: A systematic review.

Ariana Arias-Martínez, Paula Escalada-Hernández, Gustavo Adolfo Pimentel-Parra, Cristina García-Vivar, Nelia Soto-Ruiz

Abstract readSystematic Review
In one paragraph

Synthesis in Anales del sistema sanitario de Navarra, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ariana Arias-MartínezPublic University of Navarre (UPNA). Department of Health Sciences. Pamplona, Navarra. Spain.
Paula Escalada-HernándezPublic University of Navarre (UPNA). Department of Health Sciences. Pamplona, Navarra. Spain.
Gustavo Adolfo Pimentel-ParraPublic University of Navarre (UPNA). Department of Health Sciences. Pamplona, Navarra. Spain.
Cristina García-VivarPublic University of Navarre (UPNA). Department of Health Sciences. Pamplona, Navarra. Spain.
Nelia Soto-RuizPublic University of Navarre (UPNA). Department of Health Sciences. Pamplona, Navarra. Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Hormone receptor-positive breast cancer is treated with endocrine therapies to reduce recurrence and mortality. These therapies have side effects that negatively affect quality of life (QoL). We aim to synthesize the available evidence on the impact of non-pharmacological interventions on QoL and its specific domains (physical, psychological, social, and spiritual) in female breast cancer survivors undergoing endocrine therapies. Methods A systematic review following the Cochrane and PRISMA guidelines was registered in PROSPERO (CRD42024524238). Studies published from January 2013 to October 2025 were retrieved from PubMed, the Cochrane Library, Scopus, and Web of Science. Randomized controlled trials evaluating QoL in female with BC aged over 18 years, and undergoing endocrine therapies were included. Due to methodological and clinical heterogeneity, a narrative synthesis was performed instead of a meta-analysis. The RoB2 tool was used to assess the risk of bias. Results Seven studies (with 713 participants) were included. Non-pharmacological interventions such as physical exercise, hydrotherapy, physiotherapy, and health promotion programs were analysed. Physical exercise interventions showed significant improvement in overall QoL and specific domains. Conclusions Non-pharmacological interventions show variable effects on QoL in female breast cancer survivors undergoing endocrine therapies. While physical exercise appears promising, the high methodological heterogeneity and limited evidence preclude definitive conclusions. Future research should focus on standardized approaches.

Indexed as

Antineoplastic Agents, HormonalBreast NeoplasmsCancer SurvivorsQuality of LifeChemotherapy, AdjuvantFemaleHumansAntineoplastic Agents, Hormonal

Identifiers

PMID42657993
PMCPMC13588552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.